Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Short term Debt (2022 - 2025)

Historic Short term Debt for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $44.4 million.

  • NewAmsterdam Pharma's Short term Debt rose 13470.19% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year increase of 13470.19%. This contributed to the annual value of $37.5 million for FY2024, which is 19834.58% up from last year.
  • NewAmsterdam Pharma's Short term Debt amounted to $44.4 million in Q3 2025, which was up 13470.19% from $20.9 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Short term Debt registered a high of $44.4 million during Q3 2025, and its lowest value of $8414.1 during Q2 2023.
  • For the 4-year period, NewAmsterdam Pharma's Short term Debt averaged around $21.8 million, with its median value being $22.2 million (2025).
  • Per our database at Business Quant, NewAmsterdam Pharma's Short term Debt soared by 27972731.09% in 2024 and then crashed by 2884.97% in 2025.
  • NewAmsterdam Pharma's Short term Debt (Quarter) stood at $4.0 million in 2022, then surged by 216.99% to $12.6 million in 2023, then skyrocketed by 198.35% to $37.5 million in 2024, then rose by 18.25% to $44.4 million in 2025.
  • Its Short term Debt stands at $44.4 million for Q3 2025, versus $20.9 million for Q2 2025 and $23.5 million for Q1 2025.